Newron Pharmaceuticals
Manufacturing · Italy · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Via Antonio Meucci 3, Bresso, Lombardy, ...Phone Number
+39 26103461Website
www.newron.comRevenue
$10 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Newron Pharmaceuticals
Founded in 1999 and headquartered in Bresso, Italy, Newron Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain.Explore more
Newron Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Newron Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Newron Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if Newron Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Newron Pharmaceuticals
Check out if Newron Pharmaceuticals is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Newron Pharmaceuticals recently announced quarterly report
Newron Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Newron Pharmaceuticals launches new products
Funding: Get notified immidiatlly once Newron Pharmaceuticals has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Newron Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Newron Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Newron Pharmaceuticals.
Newron Pharmaceuticals financials insights
Gather financial insights about Newron Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2005
Series B
$8.1M
2020
Other Financing Round
$8.2M
2021
Debt
$8.7M
Newron Pharmaceuticals Tech Stack
A closer look at the technologies used by Newron Pharmaceuticals
Most Recent Scoops
Partnership
Newron Pharmaceuticals has partnered with ASI (Eisai) to conduct a Phase III study of evanamide in Japan targeting PMDA approval, with ASI bringing an established track record in neurology, including the development and commercialization of Leqembi in Alzheimer's disease.
Partnership
Partnership, Research & Development, Business Development, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals
Partnership
Partnership, Research & Development, Business Development, Intellectual Property, Legal Affairs, Medical Research, Pharmaceuticals
Project
Product Development, Research & Development
Event
Events
Newron Pharmaceuticals News & Media
Newron Reports Subscription for EUR 5.5 Million of Shares by Investor Group as Part of Up to EUR 38 Million Total Financing to Advance Phase 3 Evenamide Program
Total proceeds expected to fund global ENIGMA-TRS studies and extend cash runway beyond pivotal 12-week results, supporting development of evenamide as the potential first add-on therapy for treatment-resistant schizophrenia Total proceeds expected to fund global ENIGMA-TRS studies and extend cash runway beyond pivotal 12-week results, supporting development of evenamide as the potential first add-on therapy for treatment-resistant schizophreniaNewron Pharmaceuticals to Participate in H.C. Wainwright 28th Annual Global Investment Conference
MILAN, Italy and MORRISTOWN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Stefan Weber, Chief Executive Officer, will participate in the H.C. Wainwright 28th Annual Global Investment Conference:Newron announces completion of screening for enrollment in pivotal Phase 3 ENIGMA-TRS 1 study with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LRNewron Pharmaceuticals S.p.A. (VTX:NWRN) Analysts Just Slashed This Year's Estimates
Today is shaping up negative for Newron Pharmaceuticals S.p.A. ( VTX:NWRN ) shareholders, with the analysts delivering...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Newron Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Founded in 1999 and headquartered in Bresso, Italy, Newron Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain.... Read More
